MADISON, Wis., Oct. 12, 2020 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS) today announced the introduction of the Oncotype MAP™ Pan-Cancer Tissue test for patients with advanced, metastatic, ...

Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco's mission is to pursue the prevention and treatment of cancer through pioneering ...

Working from findings in the landmark TAILORx study, reseachers estimated that Oncotype DX-guided treatment could reduce the total first-year breast cancer care by nearly $50 million across the United ...

From blood tests that predict recurrence to smarter, less invasive treatments, 2025 is delivering real hope—especially for ...

PHILADELPHIA (WPVI) -- Year by year, treatment for breast cancer is evolving, becoming more effective and more individualized. There was a time when breast cancer treatment was based mostly on tumor ...

Giving the direct oral anticoagulant (DOAC) edoxaban for 12 months rather than 3 months is better for preventing thrombotic events in patients with active cancer and isolated deep-vein thrombosis (DVT ...

A new study suggests that Oncotype DX-guided treatment could reduce the cost for the first year of breast cancer care in the U.S. by about $50 million (about 2 percent of the overall costs in the ...

Title: Comprehensive comparison of prognostic signatures for breast cancer in TransATAC. Presenter: Ivana Sestak, Ph.D. Date: Friday, Dec.9, 2016: 4:15 p.m. CT. Location: S6-05; General Session 6 - ...

An update from Onco-Innovations Ltd. ( ($TSE:ONCO) ) is now available. Onco-Innovations Limited announced a non-brokered private placement to ...

VANCOUVER, BC / ACCESS Newswire / September 12, 2025 / Onco-Innovations Limited (CBOE CA:ONCO)(Frankfurt:W1H)(WKN:A3EKSZ)(OTCQB:ONNVF) ("Onco" or the "Company")is ...